Crystalline forms of a FGFR inhibitor and processes for preparing the same

Patent metadata

Field	Value
Publication number	US-11472801-B2
Application number	US-202016783839-A
Country	US
Kind code	B2
Filing date	Feb 6, 2020
Priority date	May 26, 2017
Publication date	Oct 18, 2022
Grant date	Oct 18, 2022

Abstract

The present disclosure relates to solid forms of N-{[2′-(2,6-difluoro-3,5-dimethoxyphenyl)-3′-oxo-2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-[2,7]naphthyridin]-6′-yl]methyl}acrylamide, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.

First claim

What is claimed is:

1. A process for preparing a solid form of Compound 1:

comprising:
converting Compound 8:

to Compound 9:

wherein the conversion of Compound 8 to Compound 9 comprises reacting Compound 8 with 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane, P1, and B5 in the presence of S5, wherein P1 is a transition metal catalyst, B5 is a base, and S5 is a solvent;
converting Compound 9 to Compound 10:

wherein the conversion of Compound 9 to Compound 10 comprises reacting Compound 10 with sodium periodate and osmium tetroxide in the presence of S4, wherein S4 is a solvent;
converting Compound 10 to Compound 11:

wherein the conversion of Compound 10 to Compound 11 comprises reacting Compound 11 with hydroxylamine hydrochloride in the presence of S3, wherein S3 is a solvent;
converting Compound 11 to Compound 12 diacetate:

wherein the conversion of Compound 11 to Compound 12 diacetate comprises reacting Compound 11 with acetic acid and zinc;
converting Compound 12 diacetate to Compound 12 hydrochloride:

wherein the conversion of Compound 12 diacetate to Compound 12 hydrochloride comprises reacting Compound 12 diacetate with B2 and hydrochloric acid in the presence of S2, wherein B2 is a hydroxide base and S2 is a solvent; and
converting Compound 12 hydrochloride to Compound 1, wherein the conversion of Compound 12 hydrochloride to Compound 1 comprises reacting Compound 12 hydrochloride with acryloyl chloride in the presence of B1 and S1, wherein B1 is a base and Si is a solvent;
wherein the solid form of Compound 1 is crystalline and has Form I, wherein Form I has one or more characteristic XRPD peak selected from about 8.1, about 9.0, about 11.5, about 12.3, about 15.1, about 16.0, about 18.0, about 19.6, about 20.0, about 20.4, about 21.0, about 23.3, about 24.2, about 24.7, and about 27.1 degrees 2-theta.

2. A process for preparing a solid form of Compound 1:

comprising converting Compound 12 hydrochloride:

to Compound 1, wherein the conversion of Compound 12 hydrochloride to Compound 1 comprises reacting Compound 12 hydrochloride with acryloyl chloride in the presence of B1 and S1, wherein B1 is a base and Si is a solvent;
wherein the solid form of Compound 1 is crystalline and has Form I, wherein Form I has one or more characteristic XRPD peak selected from about 8.1, about 9.0, about 11.5, about 12.3, about 15.1, about 16.0, about 18.0, about 19.6, about 20.0, about 20.4, about 21.0, about 23.3, about 24.2, about 24.7, and about 27.1 degrees 2-theta.

3. The process of claim 2 , wherein B1 is an alkali metal hydroxide base.

4. The process of claim 2 , wherein S1 comprises a halogenated solvent.

5. The process of claim 2 , wherein the conversion of Compound 12 hydrochloride to Compound 1 is carried out at a temperature of about 30° C. or lower.

6. The process of claim 2 , wherein Compound 12 hydrochloride is prepared by a process comprising converting Compound 12 diacetate:

to Compound 12 hydrochloride, wherein the conversion of Compound 12 diacetate to Compound 12 hydrochloride comprises reacting Compound 12 diacetate with B2 and hydrochloric acid in the presence of S2, wherein B2 is a hydroxide base and S2 is a solvent.

7. The process of claim 6 , wherein B2 is an alkali metal hydroxide base.

8. The process of claim 6 , wherein S2 comprises a halogenated solvent, protic solvent, or a mixture thereof.

9. The process of claim 6 wherein Compound 12 diacetate is prepared by a process comprising converting Compound 11:

to Compound 12 diacetate, wherein the conversion of Compound 11 to Compound 12 diacetate comprises reacting Compound 11 with acetic acid and zinc.

10. The process of claim 9 , wherein Compound 11 is prepared by a process comprising converting Compound 10:

to Compound 11, wherein the conversion of Compound 10 to Compound 11 comprises reacting Compound 11 with hydroxylamine hydrochloride in the presence of S3, wherein S3 is a solvent.

11. The process of claim 10 , wherein S3 comprises a protic solvent, a basic solvent, or a mixture thereof.

12. The process of claim 10 , wherein Compound 10 is prepared by a process comprising converting Compound 9:

to Compound 10, wherein the conversion of Compound 9 to Compound 10 comprises reacting Compound 10 with sodium periodate and osmium tetroxide in the presence of S4, wherein S4 is a solvent.

13. The process of claim 12 , wherein the conversion of Compound 9 to Compound 10 further comprises B4, wherein B4 is a base.

14. The process of claim 13 , wherein B4 is an alkali metal bicarbonate base.

15. The process of claim 12 , wherein S4 comprises an ether solvent, a protic solvent, an aprotic solvent, or a mixture thereof.

16. The process of claim 12 , wherein Compound 9 is prepared by a process comprising converting Compound 8:

to Compound 9, wherein the conversion of Compound 8 to Compound 9 comprises reacting Compound 8 with 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane, P1, and B5 in the presence of S5, wherein P1 is a transition metal catalyst, B5 is a base, and S5 is a solvent.

17. The process of claim 16 , wherein P1 is a palladium catalyst.

18. The process of claim 16 , wherein B5 is cesium fluoride.

19. The process of claim 16 , wherein S5 comprises a protic solvent, an ether solvent, or a mixture thereof.

20. The process of claim 2 , wherein Compound 12 hydrochloride is prepared by a process comprising converting Compound 15:

to Compound 12 hydrochloride, wherein the conversion of Compound 15 to Compound 12 hydrochloride comprises reacting Compound 15 with hydrochloric acid in the presence of S6, wherein S6 is a solvent.

21. The process of claim 20 , wherein S6 comprises an aprotic solvent, an ether solvent, or a mixture thereof.

22. The process of claim 20 , wherein Compound 15 is prepared by a process comprising converting Compound 8:

Assignees

• Incyte Corp

Inventors

• Pan Yongchun
• Shi Chongsheng Eric
• Tao Ming
• Han Wayne
• Xia Michael
• Wang Dengjin
• Jia Zhongjiang
• Zhou Jiacheng
• Li Qun

Classifications

• C07B2200/13

  Crystalline forms, e.g. polymorphs · CPC title

• A61K31/438

  The ring being spiro-condensed with carbocyclic or heterocyclic ring systems · CPC title

• A61P35/00 Primary

  Antineoplastic agents · CPC title

• C07D471/04 Primary

  Ortho-condensed systems · CPC title